{"database": "press", "table": "releases", "rows": [["https://www.grassley.senate.gov/news/news-releases/grassley-seeks-information-sec-whether-mylan-misled-investors-settlement", "Grassley Seeks Information from SEC on Whether Mylan Misled Investors on Settlement Announcement", "2016-11-21", "2016", "2016-11", "Republican", "House", "IA", "Charles Grassley", "G000386", "www.grassley.senate.gov", null, null, "legacy", "WASHINGTON \u2013 Sen. Chuck Grassley, Chairman of the Judiciary Committee, has asked the Securities and Exchange Commission to inform the Judiciary Committee on whether the commission is looking into whether Mylan misled investors in announcing a settlement on overcharging the taxpayers for EpiPens under Medicaid.\u00a0  \u00a0  \u201cIf Mylan\u2019s purpose of the press release was to increase stock prices at the risk of misleading investors, it is exactly this set of facts and circumstances that the SEC should monitor,\u201d Grassley wrote to SEC Chair Mary Jo White. \u00a0\u201cCompanies cannot be allowed to manipulate the markets and investors via press releases. Accordingly, since the SEC is already investigating Mylan, I request that you inform the Committee as to whether the SEC is looking into Mylan\u2019s press release to determine if it was materially misleading.\u201d  \u00a0  Grassley wrote that Mylan issued a press release Oct. 7 announcing the settlement with specific references to some of its alleged terms, but the Justice Department has maintained that there is no executed settlement and has been unwilling to confirm the alleged terms. \u00a0The company also filed a document called an 8-K report describing the settlement and mentioning an SEC investigation over the Medicaid overcharges.  \u00a0  \u201cThis seems to contradict Mylan\u2019s claim that all potential liability claims have been resolved. Mylan made no mention of the fact that they are under an SEC investigation in their press release,\u201d Grassley wrote. \u00a0\u201cGiven the dissonance between the press release, the 8-K filing, and the fact that no settlement agreement has been executed, Mylan should explain why it released such a strongly worded press release knowing that a finalized settlement did not yet exist and given the apparent SEC investigation. Further, it has now been over five weeks since Mylan\u2019s press release and apparently a settlement has still not been executed.\u201d  \u00a0  Grassley asked for a response by Nov. 29. \u00a0Grassley is looking into the potential settlement between the Justice Department and Mylan over hundreds of millions of dollars of overcharges to the taxpayers under the Medicaid Drug Rebate Program and the role government agencies had in regard to holding Mylan accountable for the misclassification. \u00a0Centers for Medicare and Medicaid Services officials were told in March 2009 that Mylan misclassified the EpiPen and was overcharging the taxpayers, yet the problem apparently persisted nonetheless. \u00a0Grassley is seeking accountability for the problem to help make sure it does not recur.  \u00a0  Grassley\u2019s letter to the SEC is available here. \u00a0  \u00a0  \u00a0-30-", 1, "2026-03-30T12:14:52Z", "2026-03-30T12:14:52Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://www.grassley.senate.gov/news/news-releases/grassley-seeks-information-sec-whether-mylan-misled-investors-settlement"], "units": {}, "query_ms": 1.4401189982891083, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}